Xiangjun Dou , Yan Wu , Lili Liang , Yane Yang , Fengtong Li , Xia Li , Dong Wang
{"title":"生酮饮食对新生儿低血糖导致的耐药性癫痫患儿的疗效和耐受性病例系列。","authors":"Xiangjun Dou , Yan Wu , Lili Liang , Yane Yang , Fengtong Li , Xia Li , Dong Wang","doi":"10.1016/j.yebeh.2024.110088","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The objective of this study was to investigate the effectiveness and tolerance of the ketogenic diet (KD) in children who have drug-resistant epilepsy (DRE) caused by neonatal hypoglycemia.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of the data from pediatric patients who were diagnosed with neonatal hypoglycemia-related DRE and initiated a KD at Xi’an Children’s Hospital between May 2014 and March 2023.</div></div><div><h3>Results</h3><div>Nine patients were enrolled in this study. The mean age of seizure onset was 6.16 ± 3.97 months, with a mean age of dietary therapy initiation at 21.56 ± 10.94 months and a median diet duration of nine months (range: 3–39.6 months). All of the nine patients (seven males) had daily seizures, and the most common seizure type was epileptic spasms. Magnetic resonance imaging (MRI) of the brain in all nine patients revealed bilateral atrophy of the occipital-parietal cortex, with or without gliosis. Of the patients studied, 22.2 % were classified as definite KD responders. These individuals achieved seizure freedom after one month of starting KD treatment and maintained a seizure-free state for over 22 months. One patient (11.1 %) was a partial KD responder who had a > 50 % seizure reduction within three months from KD initiation and continued the diet therapy for more than one year. None of the patients stopped taking KD because they could not tolerate the majority of the adverse effects, which were mild. At the last follow-up, six patients (66.7 %) had stopped their diet therapy with lack of efficacy being the leading cause.</div></div><div><h3>Conclusions</h3><div>KD is a safe and tolerable alternative treatment in pediatric patients with DRE secondary to neonatal hypoglycaemia. Most of the time, KD has minimal efficacy; however, diet therapy may be quite helpful for some patients. Thus, for DRE associated with neonatal hypoglycemia, KD treatment is appropriate to consider.</div></div>","PeriodicalId":11847,"journal":{"name":"Epilepsy & Behavior","volume":"161 ","pages":"Article 110088"},"PeriodicalIF":2.3000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A case series of the efficacy and tolerability of ketogenic diet in children with drug-resistant epilepsy due to neonatal hypoglycemia\",\"authors\":\"Xiangjun Dou , Yan Wu , Lili Liang , Yane Yang , Fengtong Li , Xia Li , Dong Wang\",\"doi\":\"10.1016/j.yebeh.2024.110088\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>The objective of this study was to investigate the effectiveness and tolerance of the ketogenic diet (KD) in children who have drug-resistant epilepsy (DRE) caused by neonatal hypoglycemia.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of the data from pediatric patients who were diagnosed with neonatal hypoglycemia-related DRE and initiated a KD at Xi’an Children’s Hospital between May 2014 and March 2023.</div></div><div><h3>Results</h3><div>Nine patients were enrolled in this study. The mean age of seizure onset was 6.16 ± 3.97 months, with a mean age of dietary therapy initiation at 21.56 ± 10.94 months and a median diet duration of nine months (range: 3–39.6 months). All of the nine patients (seven males) had daily seizures, and the most common seizure type was epileptic spasms. Magnetic resonance imaging (MRI) of the brain in all nine patients revealed bilateral atrophy of the occipital-parietal cortex, with or without gliosis. Of the patients studied, 22.2 % were classified as definite KD responders. These individuals achieved seizure freedom after one month of starting KD treatment and maintained a seizure-free state for over 22 months. One patient (11.1 %) was a partial KD responder who had a > 50 % seizure reduction within three months from KD initiation and continued the diet therapy for more than one year. None of the patients stopped taking KD because they could not tolerate the majority of the adverse effects, which were mild. At the last follow-up, six patients (66.7 %) had stopped their diet therapy with lack of efficacy being the leading cause.</div></div><div><h3>Conclusions</h3><div>KD is a safe and tolerable alternative treatment in pediatric patients with DRE secondary to neonatal hypoglycaemia. Most of the time, KD has minimal efficacy; however, diet therapy may be quite helpful for some patients. Thus, for DRE associated with neonatal hypoglycemia, KD treatment is appropriate to consider.</div></div>\",\"PeriodicalId\":11847,\"journal\":{\"name\":\"Epilepsy & Behavior\",\"volume\":\"161 \",\"pages\":\"Article 110088\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epilepsy & Behavior\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1525505024004700\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BEHAVIORAL SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsy & Behavior","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525505024004700","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}
A case series of the efficacy and tolerability of ketogenic diet in children with drug-resistant epilepsy due to neonatal hypoglycemia
Objective
The objective of this study was to investigate the effectiveness and tolerance of the ketogenic diet (KD) in children who have drug-resistant epilepsy (DRE) caused by neonatal hypoglycemia.
Methods
We conducted a retrospective analysis of the data from pediatric patients who were diagnosed with neonatal hypoglycemia-related DRE and initiated a KD at Xi’an Children’s Hospital between May 2014 and March 2023.
Results
Nine patients were enrolled in this study. The mean age of seizure onset was 6.16 ± 3.97 months, with a mean age of dietary therapy initiation at 21.56 ± 10.94 months and a median diet duration of nine months (range: 3–39.6 months). All of the nine patients (seven males) had daily seizures, and the most common seizure type was epileptic spasms. Magnetic resonance imaging (MRI) of the brain in all nine patients revealed bilateral atrophy of the occipital-parietal cortex, with or without gliosis. Of the patients studied, 22.2 % were classified as definite KD responders. These individuals achieved seizure freedom after one month of starting KD treatment and maintained a seizure-free state for over 22 months. One patient (11.1 %) was a partial KD responder who had a > 50 % seizure reduction within three months from KD initiation and continued the diet therapy for more than one year. None of the patients stopped taking KD because they could not tolerate the majority of the adverse effects, which were mild. At the last follow-up, six patients (66.7 %) had stopped their diet therapy with lack of efficacy being the leading cause.
Conclusions
KD is a safe and tolerable alternative treatment in pediatric patients with DRE secondary to neonatal hypoglycaemia. Most of the time, KD has minimal efficacy; however, diet therapy may be quite helpful for some patients. Thus, for DRE associated with neonatal hypoglycemia, KD treatment is appropriate to consider.
期刊介绍:
Epilepsy & Behavior is the fastest-growing international journal uniquely devoted to the rapid dissemination of the most current information available on the behavioral aspects of seizures and epilepsy.
Epilepsy & Behavior presents original peer-reviewed articles based on laboratory and clinical research. Topics are drawn from a variety of fields, including clinical neurology, neurosurgery, neuropsychiatry, neuropsychology, neurophysiology, neuropharmacology, and neuroimaging.
From September 2012 Epilepsy & Behavior stopped accepting Case Reports for publication in the journal. From this date authors who submit to Epilepsy & Behavior will be offered a transfer or asked to resubmit their Case Reports to its new sister journal, Epilepsy & Behavior Case Reports.